Pleomorphic carcinoma of the breast: Clinicopathological analysis of 26 cases of an unusual high-grade phenotype of ductal carcinoma

Histopathology

Volumn 36, Issue 6, 2000, Pages 505-514

  Silver, S A ^a,b   Tavassoli, F A ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Anaplastic carcinoma; Breast carcinoma; Ductal type; Pleomorphic carcinoma

Indexed keywords

ADULT; AGED; ANEUPLOIDY; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST DUCT; CANCER GRADING; CANCER MORTALITY; CELL CYCLE S PHASE; CELL NUCLEUS; CELL STRUCTURE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; PATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; SARCOMA; TUMOR CLASSIFICATION; TUMOR VOLUME;

EID: 0034121809     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.2000.00924.x     Document Type: Article

References (26)

1. 1. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991: 19; 403-410.
2. 2. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled (PAP) procedures. J. Histochem. Cytochem. 1981: 29; 577-580.
3. 3. Bacus SS, Bacus JW, Slamon DJ. Press MF. HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch. Pathol. Lab. Med. 1990: 114; 164-169.
4. 4. Press MF, Pike MC, Chazin VR et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993: 53; 4960-4970.
5. 5. Hedley DW, Friedlander ML, Taylor IW. Method for analysis of cellular DNA content of paraffin-embedded pathological materials using flow cytometry. J. Histochem. Cytochem. 1983: 31; 1333-1335.
6. 6. McLemore DD, El-Naggar AK, Stephens LC, Jardine J. Modified methodology to improve flow cytometric DNA histograms from paraffin-embedded material. Stain Technol. 1990: 65; 279-291.
7. 7. Barlogie B, Göhde W, Johnston DA. Determination of ploidy and proliferative characteristics of human solid tumors by pulse cytophotometry. Cancer Res. 1978: 38; 3333-3339.
8. 8. Baisch H, Göhde W, Linden WA. Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat. Environ. Biophys. 1975: 12; 31-39.
9. 9. Tavassoli FA. Classification of metaplastic carcinomas of the breast. In: Rosen PP, Fechner RD, eds. Pathology Annual. Volume 27 (part 2). Norwalk, CT: Appleton & Lange, 1992: 89-119.
10. 10. Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am. J. Surg. Pathol. 1987: 11; 918-929.
11. 11. Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum. Phatol. 1989: 20; 732-740.
12. 12. Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell carcinoma of ductal origin. Cancer 1990: 65; 272-276.
13. 13. Alsabeh R, Wilson CS, Ahn CW, Vasef MA, Battifora H. Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod. Pathol. 1996: 9; 439-444.
14. 14. Visscher DW, Sarkar F, Tabaczka P, Crissman J. Clinicopathologic analysis of bcl-2 immunostaining in breast carcinoma. Mod. Pathol. 1996: 9; 642-646.
15. 15. Barbareschi M, Leonardi E, Mauri FA, Serio G, Dalla Palma P. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am. J. Clin. Pathol. 1992: 98; 408-418.
16. 16. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum. Pathol. 1993: 24; 469-476.
17. 17. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen. Ki-67 and MIB-1. Am. J. Clin. Pathol. 1995: 104; 42-49.
18. 18. Douglas-Jones AG, Barr WT. Breast carcinoma with tumor giant cells. Report of a case with fine needle aspiration cytology. Acta Cytol. 1989: 33; 109-114.
19. 19. Gupta RK, Wakefield SJ, Lallu S, Fauck R, Simpson J, Dowle CS. Aspiration cytodiagnosis of breast carcinoma in pregnancy and lactation with immunohistochemical and electron microscopic study of an unusual mammary malignancy with pleomorphic giant cells. Diagn. Cytophatol. 1992: 8; 352-356.
20. 20. Gupta RK. Aspiration cytodiagnosis of a rare carcinoma of breast with bizarre malignant giant cells. Diagn. Cytopathol. 1996: 15; 66-69.
21. 21. Della Salda L, Sarli G, Benazzi C, Marcato PS. Giant cells in anaplastic mammary carcinoma of the dog and cat. J. Comp. Path. 1993: 109; 345-360.
22. 22. Terrier Ph, Terrier-Lacombe MJ, Mouriesse H, Friedman S, Spielmann M, Contesso G. Primary breast sarcoma: a review of 33 cases with immunohistochemistry and prognostic factors. Breast Cancer Res. Treat. 1989: 13; 39-48.
23. 23. Agnantis NT, Rosen PP. Mammary carcinoma with osteoclast-like giant cells. A study of eight cases with follow-up data. Am. J. Clin. Pathol. 1979: 72; 383-389.
24. 24. Tavassoli FA, Norris HJ. Breast carcinoma with osteoclastlike giant cells. Arch. Pathol. Lab. Med. 1986: 110; 636-639.
25. 25. Eusebi V. Magalhaes F, Azzopardi JC. Pleomorphic lobular carcinoma of the breast: an aggressive tumor showing apocrine differentiation. Hum. Pathol. 1992: 23; 655-662.
26. 26. Weidner N, Semple JP. Pleomorphic variant of invasive lobular carcinoma of the breast. Hum. Pathol. 1992: 23; 1167-1171.